# Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients
Canonical URL: https://biopharmsignal.com/news/IRON/disc-medicine-launches-expanded-access-program-for-bitopertin-for-epp-patients
Ticker: IRON
Company: Disc Medicine
Source: Disc Medicine
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.discmedicine.com
## Summary

The expanded access program (EAP) is available to eligible patients with erythropoietic protoporphyria (EPP) and provides access to bitopertin prior to regulatory decision Bitopertin, an oral glycine transporter 1 (GlyT1) inhibitor, is being evaluated in the Phase 3 APOLLO clinical trial, with

## Article Body
The expanded access program (EAP) is available to eligible patients with erythropoietic protoporphyria (EPP) and provides access to bitopertin prior to regulatory decision Bitopertin, an oral glycine transporter 1 (GlyT1) inhibitor, is being evaluated in the Phase 3 APOLLO clinical trial, with
## Recent Company News
- 2026-06-25 13:46 EST — [Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting](https://biopharmsignal.com/news/IRON/disc-medicine-presents-positive-clinical-updates-at-the-2026-european-hematology-association-eha-annual-meeting) — Source: Disc Medicine
- 2026-06-25 13:46 EST — [Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria](https://biopharmsignal.com/news/IRON/disc-medicine-provides-update-from-fda-type-a-meeting-for-bitopertin-in-erythropoietic-protoporphyria) — Source: Disc Medicine
- 2026-06-25 13:46 EST — [Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients](https://biopharmsignal.com/news/IRON/disc-medicine-launches-expanded-access-program-for-bitopertin-for-epp-patients) — Source: Disc Medicine
- 2026-06-25 13:46 EST — [Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting](https://biopharmsignal.com/news/IRON/disc-medicine-presents-updated-positive-data-from-rally-mf-phase-2-trial-in-patients-with-myelofibrosis-mf-and-anemia-at-the-2026-american-society-of-clinical-oncology-asco-annual-meeting) — Source: Disc Medicine
- 2026-06-25 13:46 EST — [Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress](https://biopharmsignal.com/news/IRON/disc-medicine-announces-multiple-presentations-across-portfolio-at-the-european-hematology-association-eha-2026-congress) — Source: Disc Medicine
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)